



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_307_24

You asked:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Aromatase Inhibitor as a single agent
- Atezolizumab
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Transtuzumab deruxtecan
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

Q2. If breast cancer is not treated at or within the Health Board, where are patients referred?

Our response:

We can confirm that Cwm Taf Morgannwg University Health Board does not hold the information you require. Cwm Taf Morgannwg residents receive Oncology Breast Cancer treatments from the Velindre Cancer Centre, Velindre NHS Trust. Therefore, you will need to redirect your request to Velindre, who provide these services to Cwm Taf Morgannwg residents.

Contact details for Velindre are shown in the following link:

[Freedom of information contacts - Velindre University NHS Trust](#)